NZ552274A - Aequorin-containing compositions and methods of using same - Google Patents
Aequorin-containing compositions and methods of using sameInfo
- Publication number
- NZ552274A NZ552274A NZ552274A NZ55227405A NZ552274A NZ 552274 A NZ552274 A NZ 552274A NZ 552274 A NZ552274 A NZ 552274A NZ 55227405 A NZ55227405 A NZ 55227405A NZ 552274 A NZ552274 A NZ 552274A
- Authority
- NZ
- New Zealand
- Prior art keywords
- aequorin
- calcium
- compositions
- symptom
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/872,795 US20060229243A1 (en) | 2004-06-21 | 2004-06-21 | Aequorin-containing compositions and methods of using same |
| PCT/US2005/021770 WO2006010004A2 (en) | 2004-06-21 | 2005-06-21 | Aequorin-containing compositions and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ552274A true NZ552274A (en) | 2010-06-25 |
Family
ID=35785748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ552274A NZ552274A (en) | 2004-06-21 | 2005-06-21 | Aequorin-containing compositions and methods of using same |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20060229243A1 (https=) |
| EP (2) | EP2545934B1 (https=) |
| JP (1) | JP4971150B2 (https=) |
| KR (1) | KR101213555B1 (https=) |
| CN (1) | CN1997383B (https=) |
| AU (1) | AU2005265266B2 (https=) |
| BR (1) | BRPI0512392B1 (https=) |
| CA (1) | CA2571542C (https=) |
| CY (1) | CY1114307T1 (https=) |
| DK (1) | DK1768691T3 (https=) |
| ES (1) | ES2422173T3 (https=) |
| IL (1) | IL180195A (https=) |
| MX (1) | MXPA06015037A (https=) |
| NZ (1) | NZ552274A (https=) |
| PL (1) | PL1768691T3 (https=) |
| PT (1) | PT1768691E (https=) |
| SG (1) | SG153848A1 (https=) |
| SI (1) | SI1768691T1 (https=) |
| WO (1) | WO2006010004A2 (https=) |
| ZA (1) | ZA200610688B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060229243A1 (en) * | 2004-06-21 | 2006-10-12 | Quincy Resource Group, Inc. | Aequorin-containing compositions and methods of using same |
| GB0625678D0 (en) | 2006-12-21 | 2007-01-31 | Lux Biotechnology Ltd | Composition and method for detection of demineralisation |
| BRPI0909435A2 (pt) | 2008-03-11 | 2017-06-13 | Quincy Bioscience Llc | composição e método para tratar de um sintoma ou distúrbio associado com o desequilíbrio do cálcio, uso da apoequorina, e, apoaequorina |
| JP2010143860A (ja) * | 2008-12-19 | 2010-07-01 | Chisso Corp | タンパク質の安定化剤 |
| US20110130336A1 (en) * | 2009-10-16 | 2011-06-02 | Quincy Bioscience, Llc | Method of treating ischemic injury using apoaequorin |
| US9316588B2 (en) * | 2010-12-24 | 2016-04-19 | Otsuka Pharmaceutical Co., Ltd. | Bioassay method for detecting physiologically active substance |
| KR102009932B1 (ko) * | 2011-11-15 | 2019-08-12 | 퀸시 바이오사이언스 엘엘씨 | 허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린 |
| GB201700317D0 (en) | 2017-01-09 | 2017-02-22 | Calcivis Ltd | Detection device |
| USD1042180S1 (en) | 2020-05-28 | 2024-09-17 | Calcivis Limited | Dental detection device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001240855A (ja) * | 2000-03-01 | 2001-09-04 | Masashi Sugimoto | 生物発光方法及び発光物品 |
| US6800492B2 (en) * | 2000-06-01 | 2004-10-05 | Institute Pasteur | Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level |
| WO2001096361A1 (en) * | 2000-06-12 | 2001-12-20 | University Of Maryland Biotechnology Institute | Method of controlling the binding of calmyrin to presenilin |
| US20060229243A1 (en) * | 2004-06-21 | 2006-10-12 | Quincy Resource Group, Inc. | Aequorin-containing compositions and methods of using same |
-
2004
- 2004-06-21 US US10/872,795 patent/US20060229243A1/en not_active Abandoned
-
2005
- 2005-06-21 SG SG200904273-0A patent/SG153848A1/en unknown
- 2005-06-21 JP JP2007518179A patent/JP4971150B2/ja not_active Expired - Fee Related
- 2005-06-21 NZ NZ552274A patent/NZ552274A/en not_active IP Right Cessation
- 2005-06-21 US US11/571,043 patent/US7671015B2/en not_active Expired - Lifetime
- 2005-06-21 KR KR1020077001461A patent/KR101213555B1/ko not_active Expired - Lifetime
- 2005-06-21 BR BRPI0512392-5A patent/BRPI0512392B1/pt active IP Right Grant
- 2005-06-21 DK DK05766584.6T patent/DK1768691T3/da active
- 2005-06-21 MX MXPA06015037A patent/MXPA06015037A/es active IP Right Grant
- 2005-06-21 EP EP12188025.6A patent/EP2545934B1/en not_active Expired - Lifetime
- 2005-06-21 SI SI200531724T patent/SI1768691T1/sl unknown
- 2005-06-21 PL PL05766584T patent/PL1768691T3/pl unknown
- 2005-06-21 ES ES05766584T patent/ES2422173T3/es not_active Expired - Lifetime
- 2005-06-21 PT PT57665846T patent/PT1768691E/pt unknown
- 2005-06-21 AU AU2005265266A patent/AU2005265266B2/en not_active Expired
- 2005-06-21 EP EP05766584.6A patent/EP1768691B1/en not_active Expired - Lifetime
- 2005-06-21 CA CA2571542A patent/CA2571542C/en not_active Expired - Lifetime
- 2005-06-21 WO PCT/US2005/021770 patent/WO2006010004A2/en not_active Ceased
- 2005-06-21 CN CN200580024585XA patent/CN1997383B/zh not_active Expired - Lifetime
-
2006
- 2006-12-19 ZA ZA200610688A patent/ZA200610688B/en unknown
- 2006-12-19 IL IL180195A patent/IL180195A/en active IP Right Grant
-
2010
- 2010-01-27 US US12/694,427 patent/US20100152117A1/en not_active Abandoned
-
2013
- 2013-06-14 CY CY20131100486T patent/CY1114307T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100152117A1 (en) | Aequorin-Containing Compositions and Methods of Using Same | |
| CA2717322C (en) | Apoaequorin-containing compositions and methods of using same | |
| US12005096B2 (en) | Apoaequorin and vitamin d-containing compositions and methods of using same | |
| HK1180974A (en) | Aequorin-containing compositions and methods of using same | |
| CA3037892C (en) | Apoaequorin and vitamin d-containing compositions and methods of using same | |
| HK1109576B (en) | Aequorin-containing compositions and methods of using same | |
| HK1238166A1 (en) | Apoaequorin-containing compositions and methods of using same | |
| HK1154217A (zh) | 含有脱辅基水母蛋白的组合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2016 BY CPA GLOBAL Effective date: 20150511 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2017 BY CPA GLOBAL Effective date: 20160506 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2018 BY AJ PARK Effective date: 20170510 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2019 BY AJ PARK Effective date: 20180619 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2020 BY AJ PARK Effective date: 20190612 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2021 BY AJ PARK Effective date: 20200527 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2022 BY AJ PARK Effective date: 20210526 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2023 BY AJ PARK Effective date: 20220422 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2024 BY AJ PARK Effective date: 20230602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JUN 2025 BY AJ PARK Effective date: 20240529 |
|
| EXPY | Patent expired |